Cite

HARVARD Citation

    Segman, Y. et al. (2021). Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience. Leukemia & lymphoma. 62 (1), pp. 118-124. [Online]. 
  
Back to record